Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Arthritis Care & Research|August 9, 2013
Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophyGulnara Mamyrova, James D Katz, Robert V Jones, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 19, 2023
Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept TherapyRodolfo V Curiel, William Nguyen, Gulnara Mamyrova, et al.
Annals of Hematology|April 17, 2023
Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantationMuzaffer Keklik, Burak Deveci, Serhat Celik, et al.
Seminars in Arthritis and Rheumatism|July 16, 2019
Long-term outcomes in Juvenile Myositis patientsVladislav Tsaltskan, Annette Aldous, Sam Serafi, et al.
Arthritis and Rheumatism|May 30, 2006
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritisDaniel J Lovell, Andreas Reiff, Olcay Y Jones, et al.
Arthritis and Rheumatism|January 16, 2003
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trialDaniel J Lovell, Edward H Giannini, Andreas Reiff, et al.
Frontiers in Immunology|November 28, 2022
A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™)Fethi Gül, Zeynep Burcin Gonen, Olcay Y Jones, et al.
Frontiers in Medical Technology|March 20, 2023
Assessment of a novel continuous cleaning device using metatranscriptomics in diverse hospital environmentsJustin R Wright, Truc T Ly, Karen B Cromwell, et al.
RMD Open|July 16, 2020
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexateDaniel J Lovell, Hermine I Brunner, Andreas O Reiff, et al.
Annals of the Rheumatic Diseases|May 27, 2022
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonistMicol Romano, Z Serap Arici, David Piskin, et al.
Pageof 4